Bioventus BVS
$ 11.31
-2.42%
Quarterly report 2024-Q3
added 11-05-2024
Country |
USA |
IPO year |
2021 |
Industry |
Diagnostics research |
Stock Exchange |
NASDAQ GLOBAL |
CEO |
Dr. Henry C. Tung |
Employees in the company |
- |
Shares |
62.6 M |
Market Cap[1] |
$ 709 M |
EBITDA (LTM) |
$ 682 K |
P/E (LTM) |
-17.92 |
P/S (LTM) |
1.31 |
EPS (LTM) |
-0.63 |
Other stocks of industry "Diagnostics research"
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.